A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
Latest Information Update: 06 Jun 2025
At a glance
- Drugs ABBV 1088 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 20 May 2025 Planned End Date changed from 12 Nov 2025 to 1 Nov 2025.
- 20 May 2025 Planned primary completion date changed from 12 Nov 2025 to 1 Nov 2025.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.